Breaking Down Barriers: How Understanding Celiac Disease Pathogenesis Informed the Development of Novel Treatments.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic literature and clinical trials without systematic review methodology
PubMed 31076989 · doi:10.1007/s10620-019-05646-y
What was done
This narrative review synthesized preclinical and clinical literature examining the role of intestinal paracellular permeability in chronic inflammatory and autoimmune conditions, focusing on celiac disease as a paradigm. It evaluated mechanistic data on gliadin-induced zonulin pathway activation and summarized findings from clinical trials testing the zonulin inhibitor larazotide acetate.
What was found
The abstract reports no numerical data, effect estimates, or statistical results. It summarizes qualitative mechanistic findings that gliadin triggers tight junction disassembly through zonulin pathway upregulation, and notes that larazotide acetate acts as an antagonist to inhibit this barrier disruption.
Why it matters
It provides a disease paradigm for how mucosal barrier dysfunction and antigen trafficking contribute to autoimmunity, highlighting tight junction modulation as a potential drug target alongside dietary gluten avoidance.
Limits
As a narrative review, it lacks systematic search criteria, quality appraisal, and meta-analytic pooling. The abstract does not specify the number of included studies, sample sizes, patient characteristics, or quantitative clinical trial outcomes.
Cited by
- supports Gliadin is a major protein in bread that triggers an immune cascade resulting in increased intestinal permeability in genetically susceptible individuals with celiac disease.